Premium
Temozolomide plus thalidomide in patients with brain metastases from melanoma
Author(s) -
Hwu WenJen,
Lis Eric,
Menell Jennifer H.,
Panageas Katherine S.,
Lamb Lynne A.,
Merrell Janene,
Williams Linda J.,
Krown Susan E.,
Chapman Paul B.,
Livingston Philip O.,
Wolchok Jedd D.,
Houghton Alan N.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21081
Subject(s) - medicine , temozolomide , surgery , thalidomide , brain metastasis , concomitant , melanoma , regimen , chemotherapy , radiation therapy , progressive disease , phases of clinical research , craniotomy , cancer , metastasis , multiple myeloma , cancer research
BACKGROUND Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma. The current Phase II study examined the efficacy and safety of this combination in chemotherapy‐naive patients with brain metastases. METHODS Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m 2 per day for 6 weeks with a 2‐week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients ≥ 70 years). The primary end point was tumor response in the brain assessed every 8 weeks. RESULTS Twenty‐six patients with a median age of 60 years were treated. All patients had progressive brain metastases: 16 were symptomatic and 25 had extensive extracranial metastases. Eight patients had received whole‐brain radiotherapy, 4 had received stereotactic radiotherapy, and 8 had received craniotomy with resection of hemorrhagic lesions. Fifteen patients completed ≥ 1 cycle (median, 1 cycle; range, 0–4 cycles), and 11 discontinued treatment before completing 1 cycle (7 for intracranial hemorrhage, 2 for pulmonary embolism, 1 for deep vein thrombosis, and 1 for Grade 3 rash). Of 15 patients assessable for response, 3 had a complete or partial response (12% intent to treat) and 7 had minor response or stable disease in the brain. However, 5 of these 10 patients had disease progression at extracranial sites. The median survival period was 5 months for all 26 patients and 6 months for the 15 assessable patients. CONCLUSIONS Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma. Cancer 2005. © 2005 American Cancer Society.